<DOC>
	<DOCNO>NCT02426541</DOCNO>
	<brief_summary>This 8-week , single centre , randomize , parallel-group , double-blind , placebo-controlled Phase IV study evaluate effect dapagliflozin tissue specific insulin sensitivity patient Type 2 diabetes mellitus .</brief_summary>
	<brief_title>Effects Dapagliflozin 10 mg Insulin Resistance Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Main 1 . Provision sign informed consent prior study specific procedure . 2 . Female male age 35 70 year inclusive suitable vein cannulation repeat venipuncture 3 . Type 2 Diabetes mellitus define HbA1c ≥ 6.5 % ≤ 10.5 % . 4 . Stable ( ≥ 3 month ) T2D treatment metformin and/or metformin+dipeptidyl peptidase4 inhibitor ( DPPIV ) 5 . Body mass index ( BMI ) ≤ 40 kg/m2 . 6 . Female subject must nonchildbearing potential , meet least one follow criterion : 1 . Hysterectomized females 2 . Postmenopausal woman , define woman menstrual period within 1 year Main 1 . Any condition contraindicate MRI , limit , pacemaker claustrophobia . 2 . Volume deplete patient . Patients risk volume depletion due coexist condition concomitant medication , loop diuretic careful monitoring volume status . 3 . Recent Cardiovascular Events patient : Acute Coronary Syndrome ( ACS ) within 2 month prior enrolment Hospitalization unstable angina acute myocardial infarction within 2 month prior enrolment Acute Stroke Transient Ischemic Attack ( TIA ) within two month prior enrolment Less two month post coronary artery revascularization 4 . Congestive heart failure define New York Heart Association ( NYHA ) class IV , unstable acute congestive heart failure . 5 . Blood pressure enrolment : Systolic BP ≥165 mm Hg and/or diastolic BP ≥100 mm Hg 6 . Any clinically significant illness , medical surgical procedure trauma within 4 week first administration investigational product . 7 . On insulin , GLP1 oral antidiabetic drug treatment ( metformin metformin DPPIV allow ) use medication know affect glucose metabolism . 8 . Any clinically significant abnormality physical examination , Electrocardiography ( ECG ) clinical chemistry result judge investigator . The follow specific exclusion criterion apply select Clinical Chemistry result : 1 . Creatinine clearance &lt; 60mL/min ( estimate CockroftGault formula ) . 2 . Severe hepatic insufficiency and/or significant abnormal liver function define aspartate aminotransferase ( AST ) &gt; 3x upper limit normal ( ULN ) and/or alanine aminotransferase ( ALT ) &gt; 3x ULN . 3 . Total bilirubin ( TB ) &gt; 2.0 mg/dL ( 34.2 µmol/L ) . 9 . Body weight loss great 5 % within 3 month prior Visit 1 . 10 . Previous PET scan 11 . History presence ( find Visit 1 ) clinically significant disease , disorder condition , opinion investigator , may either put subject risk participation study , influence result subject 's ability participate study .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Dapagliflozin</keyword>
	<keyword>Placebo</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Insulin sensitivity</keyword>
</DOC>